

| カタログ番号 | HB011014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 説明 |
Anti-CD22 Polyclonal Antibody (HB011014) is a rabbit polyclonal antibody detecting CD22 in ELISA, IHC, WB. Suitable for Human, Pan paniscus, Pan troglodytes, and Pongo pygmaeus.
Highlights
|
||||||||
| 種反応性 | Human | ||||||||
| アプリケーション | ELISA, IHC, WB | ||||||||
| 宿主種 | Rabbit | ||||||||
| クローン性 | Polyclonal | ||||||||
| アイソタイプ | IgG | ||||||||
| 免疫原 | E. coli - derived recombinant Human CD22 (Trp176-Ala330). | ||||||||
| ターゲット | B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, CD22, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14 | ||||||||
| エンドトキシンレベル | Please contact with the lab for this information. | ||||||||
| 純度 | >90% as determined by SDS-PAGE. | ||||||||
| 精製 | Purified by antigen affinity column. | ||||||||
| アクセッション番号 | P20273 | ||||||||
| 形態 | Liquid | ||||||||
| 保存バッファー | 0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
||||||||
| 製品使用情報 |
| ||||||||
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. | ||||||||
| 背景 | B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755 2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166 3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905 4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366 | ||||||||
| 注意事項 | For research use only. |
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206

中文
English
한국어
日本語
Español
Français
Русский